| 1 |
Murray P, Hall J. Renal replacement therapy for acute renal failure[J]. Am J Respir Crit Care Med, 2000, 162(3 Pt 1): 777-781.
|
| 2 |
Bellomo R, Cass A, Cole L, et al. Intensity of continuous renal-replacement therapy in critically ill patients[J]. N Engl J Med, 2009, 361(17): 1627-1638.
|
| 3 |
Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial[J]. Lancet, 2000, 356(9223): 26-30.
|
| 4 |
Schetz MR. Coagulation disorders in acute renal failure[J]. Kidney Int suppl, 1998, 66(5): S96-S101.
|
| 5 |
Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy[J]. Crit Care, 2007, 11(4): 218.
|
| 6 |
Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 2008,133 (Suppl 6): 141S-159S.
|
| 7 |
Fischer KG. Essentials of anticoagulation in hemodialysis[J]. Hemodial Int, 2007, 11(2): 178-189.
|
| 8 |
Novacek G, Kapiotis S, Jilma B, et al. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin[J]. Thromb Res, 1997, 88(3): 283-290.
|
| 9 |
Cardigan RA, McGloin H, Mackie IJ, et al. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration[J]. Kidney Int, 1999, 55(4): 1568-1574.
|
| 10 |
Singer M, McNally T, Screaton G, et al. Heparin clearance during continuous veno-venous haemofiltration[J]. Intens Care Med , 1994, 20(3): 212-215.
|
| 11 |
Davies H, Leslie G. Maintaining the CRRT circuit: non-anticoagulant alternatives[J]. Aust Crit Care, 2006, 19(4): 133-138.
|
| 12 |
Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators[J]. Intensive Care Med, 2007, 33(9): 1563-1570.
|
| 13 |
Greaves M, Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis[J]. Thromb Haemost, 2002, 87(1): 163-164.
|
| 14 |
Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and lowmolecular weight heparin: mechanisms of action, pharmacokinetics,dosing, monitoring, efficacy, and safety[J]. Chest, 2001, 119(Suppl 1): 64S-94S.
|
| 15 |
Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 133(Suppl 6): 340S-380S.
|
| 16 |
van der Voort PH, Gerritsen RT, Kuiper MA, et al. Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation[J]. Blood Purif, 2005, 23(3): 175-180.
|
| 17 |
Davenport A. Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments[J]. Nephrology (Carlton), 2009, 14(5): 455-461.
|
| 18 |
Joannidis M, Bellmann R. Exonaparin versus unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration–a randomized controlled cross-over study[J]. Intensive Care Med, 2007, 33(9): 1571-1579.
|
| 19 |
Mehta RL, McDonald BR, Aguilar MM, et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients[J]. Kidney Int, 1990, 38(5): 976-981.
|
| 20 |
Kramer L, Bauer E, Joukhadar C, et al.Citrate pharmacokinetics and metabolism in cirrhotic and non-cirrhotic critically ill patients[J]. Crit Care Med, 2003, 31(10): 2450-2455.
|
| 21 |
Brophy PD, Somers MJ, Baum MA, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT)[J]. Nephrol Dial Transplant, 2005, 20(7): 1416-1421.
|
| 22 |
Bagshaw SM, Laupland KB, Boiteau PJ, et al. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system[J]. J Crit Care, 2005, 20(2): 155-161.
|
| 23 |
Vargas Hein O, von Heymann C, Lipps M, et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy[J]. Intensive Care Med, 2001, 27(4): 673-679.
|
| 24 |
Reddy BV, Grossman EJ, Trevino SA, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy[J]. Ann Pharmacother, 2005, 39(10): 1601-1605.
|
| 25 |
Balik M, Waldauf P, Plásil P, et al. Prostacyclin versus citrate in continuous hemodiafiltration: an observational study in patients with high risk of bleeding[J]. Blood Purif, 2005, 23(4): 325-329.
|
| 26 |
Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane[J]. Ther Apher Dial, 2003, 7(5): 483-485.
|